Cons Of 'Brexit' For Pharma Could Far Outweigh Pros
The pharma and health policy consequences of a possible "Brexit" – i.e. the departure of the U.K. from the European Union – were discussed by a variety of stakeholders earlier this month. The U.K.'s recent general gave Prime Minister David Cameron a mandate to hold an EU referendum by the end of 2017.
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.